BioSpace News Archive

Pharm Country

New data shows benefit of lupus drug

The Feinstein Institutes for Medical Research Professor Richard Furie, MD, will publish and present data describing the clinical benefit of anifrolumab for patients with lupus in Lancet Rheumatology and at the American College of Rheumatology’s Annual Scientific Meeting.

November 11, 2019
·
2 min read
Pharm Country

Global Clinical Study Sponsors and Clinical Research Organizations Gather for the “Era of Life Science Transformation” at Medidata NEXT NYC 2019

Medidata NEXT NYC, the premier conference on the digital transformation of life sciences, is set for November 12-13 at Spring Studios in New York City.

November 11, 2019
·
2 min read
Pharm Country

New Analysis Shows Icosapent Ethyl (Vascepa®) Is Cost Effective and Offers Rare Finding of Better Outcomes at Lower Healthcare Costs When Used to Treat High-Risk Patients with Cardiovascular Disease or Diabetes and Other Risk Factors

Amarin Corporation plc (NASDAQ: AMRN) announced today a summary of results from a patient-level, cost-effectiveness analysis of icosapent ethyl (Vascepa®)

November 11, 2019
·
16 min read
Biotech Beach

NKMax America Announces Executive Advisory Board

NKMax America, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell therapies, today announced that it has brought together an unparalleled group of thought leaders to provide expertise to the NKMax senior leadership team.

November 11, 2019
·
4 min read
Business

Survey: More than Half of Male Patients with Lupus Report Feeling Depressed, Receiving Little Support

A national survey of male patients with lupus finds the illness has a significant impact on their physical and emotional health, yet they often do not receive support that could help them cope.

November 11, 2019
·
6 min read
Policy

Merck’s ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Union

Merck Remains Committed to Working with International Health Partners in Ebola Outbreak Response

November 11, 2019
·
7 min read
Drug Development

Mallinckrodt Presents Positive Phase 3 Results from its CONFIRM Study of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1) at The Liver Meeting® 2019

The CONFIRM abstract was selected by the AASLD Selection Committee for the “Best of the Liver Meeting” educational program in the portal hypertension / cirrhosis category

November 11, 2019
·
10 min read
Business

SI-BONE, Inc. Reports Third Quarter 2019 Financial Results and Updates Full-Year 2019 Revenue Guidance

SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, reported financial results for the quarter ended September 30, 2019.

November 11, 2019
·
5 min read
Business

ImmuCell Announces Unaudited Financial Results for Third Quarter of 2019

ImmuCell Corporation announced unaudited financial results for the third quarter and nine-month period ended September 30, 2019.

November 11, 2019
·
11 min read
Deals

Reata Announces Positive Topline Year One Results From Pivotal Phase 3 Cardinal Study of Bardoxolone Methyl in Patients With Alport Syndrome

Achieved key secondary endpoint of statistically significant improvement in retained EGFR compared to placebo after 48 weeks of treatment and withdrawal of drug for 4 weeks

November 11, 2019
·
11 min read